

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

**Form 8-K**

Current Report  
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 18, 2019

**FENNEC PHARMACEUTICALS INC.**

(Exact name of registrant as specified in its charter)

001-32295  
(Commission File Number)

British Columbia, Canada  
(State or other jurisdiction of  
incorporation)

20-0442384  
(I.R.S. Employer Identification No.)

PO Box 13628, 68 TW Alexander Drive,  
Research Triangle Park, NC  
(Address of principal executive offices)

27709  
(Zip Code)

Registrant's telephone number, including area code: (919) 636-4530

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

**Item 8.01 Other Events**

Exhibits.

<u>Exhibit No.</u>	<u>Description</u>
--------------------	--------------------

<a href="#">99.1</a>	<a href="#">Notice of Meeting and Record Date</a>
----------------------	---

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

FENNEC PHARMACEUTICALS INC.

Date April 18, 2019

By: /s/ Robert Andrade  
Robert Andrade  
Chief Financial Officer

---



100 University Avenue, 8th floor  
 Toronto ON, M5J 2Y1  
[www.computershare.com](http://www.computershare.com)

Date: April 18, 2019

To: All Canadian Securities Regulatory Authorities

**Subject: FENNEC PHARMACEUTICALS INC.**

Dear Sir/Madam:

We advise of the following with respect to the upcoming Meeting of Security Holders for the subject Issuer:

Meeting Type :	Annual General and Special Meeting
Record Date for Notice of Meeting :	May 14, 2019
Record Date for Voting (if applicable) :	May 14, 2019
Beneficial Ownership Determination Date :	May 14, 2019
Meeting Date :	June 18, 2019
Meeting Location (if available) :	New York, NY
Issuer sending proxy related materials directly to NOBO:	No
Issuer paying for delivery to OBO:	Yes

**Notice and Access (NAA) Requirements:**

NAA for Beneficial Holders	No
NAA for Registered Holders	No

**Voting Security Details:**

Description	CUSIP Number	ISIN
COMMON SHARES	31447P100	CA31447P1009

Sincerely,

**Computershare**

Agent for FENNEC PHARMACEUTICALS INC.

---